Fig. 1From: A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patientsEvofosfamide decreases the hypoxic fraction in a Rhabdomyosarcoma rat model. PET-scans with hypoxia tracer 18F-HX4 were made before (day 0) and after (day 4) administering evofosfamide for four consecutive days at a dose of 25 mg/kgBack to article page